Brand Reference: Vyleesi
| Metric | Verified Benchmark | Source |
|---|---|---|
| Bremelanotide (PT-141 Autoinjector) RxNorm Concept ID | 2179923 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $198.0000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $890.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $149.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $165.00 / mo | 16 Zero-PHI Verified Patient Logs |
Cyclic heptapeptide analogue of alpha-MSH that crosses into medial preoptic hypothalamic nuclei to activate melanocortin-4 (MC4R) receptors, stimulating presynaptic dopamine release across central sexual desire and arousal pathways independently of peripheral vascular nitric oxide.
Across 16 community cost disclosures for Bremelanotide (PT-141 Autoinjector) (Vyleesi), cash buyers routing around $890.00 retail markups capture a 81% discount ($165.00/mo benchmark vs $198.0000 NADAC acquisition).
Following administration (1.75 mg SC abdomen/thigh >= 45 min pre-activity (max 1 dose/24h, <= 8 doses/month)), Bremelanotide (PT-141 Autoinjector) achieves 100% subcutaneous autoinjector bioavailability and 45–60 minutes prior to anticipated activity; lasts ~12–18 hours onset, governed by a 2.7 hours terminal half-life through multiple endogenous peptide amide hydrolyses.
Before initiating Bremelanotide (PT-141 Autoinjector) at 1.75 mg SC abdomen/thigh >= 45 min pre-activity (max 1 dose/24h, <= 8 doses/month), clinical safety checklists rule out uncontrolled hypertension (causes transient +6/+3 mmhg systolic/diastolic rise and -2 bpm bradycardia). Logged tolerability patterns center on transient nausea (40% first dose) (36% of reports), facial flushing (21% of reports), focal gingival hyperpigmentation if >8x/mo (6% of reports).
Across 16 verified cash-pay logs, Bremelanotide (PT-141 Autoinjector) achieves a 81.40% Worth-It rating with out-of-pocket spend averaging $165.00/mo versus $890.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Compounding at 1.75 mg SC abdomen/thigh >= 45 min pre-activity (max 1 dose/24h, <= 8 doses/month) for Bremelanotide (PT-141 Autoinjector); monthly out-of-pocket dropped to $145.20 compared with $890.00 retail.
Completed 10 weeks on Bremelanotide (PT-141 Autoinjector) (1.75 mg SC abdomen/thigh >= 45 min pre-activity (max 1 dose/24h, <= 8 doses/month)). Zero notable side effects on steady dosing.
Consistent biomarker response on 1.75 mg SC abdomen/thigh >= 45 min pre-activity (max 1 dose/24h, <= 8 doses/month) Bremelanotide (PT-141 Autoinjector) sourced via Cost Plus Drugs ($191.40/mo cash pay without insurance prior authorization).